Bayer's Weinand On Pricing, Payers And Pipelines
Executive Summary
Bayer's pharma president and board member Dieter Weinand talks to Scrip about the importance of big picture thinking when weighing the value of innovative drugs to healthcare systems, the revolutionary potential of big data and how "transparency and open dialogue will further enhance the understanding of our business."
You may also be interested in...
Loxo’s Tissue-Agnostic Approach Brings $400m Upfront From Bayer
The German pharma signs collaboration to develop and commercialize larotrectinib and a follow-on, under a structure that enables Loxo to co-promote in the US and build commercial infrastructure.
Bayer's Aliqopa Approval Gives PI3K Class A Second Chance in Follicular Lymphoma
Bayer's PI3 kinase inhibitor copanlisib now has accelerated approval in a common type of non-Hodgkin lymphoma, but the drug's competitive profile still awaits Phase III data.
COMPASS Sets Course For J&J/Bayer's Xarelto In Unexplored Indications
A large new market in coronary artery and peripheral arterial disease beckons after Xarelto showed a 24% reduction in the risk of major cardiac events, a benefit that may outweigh the increase in major bleeding.